To evaluate the in-vivo safety and efficacy of a hair care formulation in terms of hair growth i.e. improvement in AT ratio on healthy human subjects. - NI

Mountain valley springs India pvt. ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

研究概览

暂无简介。

•1.Indian / Asian male & female subjects.
•2.Healthy subjects
•3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
•4.Having androgenetic alopecia of class I-2 to I-4 according to Ludwig Scale for females and class II to III (including III, IIIA and IIIvertex) according to Norwood Hamilton Scale for males.

•1.For Females: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
•2.Having refused to give his/her assent by not signing the consent form
•3.Taking part in another study liable to interfere with this study
•4.Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area
•5.Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months)
•6.Having a progressive asthma (either under treatment or last fit in the last 2 years)
•7.Being epileptic
•8.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
•9.Having cutaneous hypersensitivity
•10.Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products
•11.Following a chronic or intermittent medicinal treatment comprising any of the following products:aspirin-based products, anti-inflammatories, antihistamines, anti-coagulants, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)
•12.Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months

发起方

Mountain valley springs India pvt. ltd.